Nachrichten zur Intra-Cellular Therapies Inc. Aktie

J&J’s Top Rating at Risk Because of Intra-Cellular Deal

Johnson & Johnson, one of the last US companies with top credit ratings, is at risk of losing its AAA…

These Stocks Are Moving the Most Today: Nvidia, Tesla, Moderna, Intra-Cellular Therapies, D-Wave Quantum, Edison, U.S. Steel, and More

…

J&J to buy Intra-Cellular Therapies for $14.6 billion

Johnson & Johnson said on Monday it would buy drugmaker Intra-Cellular Therapies for about $14.6 billion, boosting its presence in…

Johnson & Johnson eyes $10bn acquisition of Intra-Cellular Therapies

Johnson & Johnson (NYSE:JNJ) is reportedly in talks to acquire neuroscience-focused biotech firm Intra-Cellular Therapies for $10bn. If completed, the…

J&J explores takeover bid for Intra-Cellular Therapies, Bloomberg reports By Investing.com

J&J explores takeover bid for Intra-Cellular Therapies, Bloomberg reports…

J&J Is in Talks to Buy $10 Billion Biotech Intra-Cellular

Johnson & Johnson is in talks to acquire Intra-Cellular Therapies Inc., a biopharmaceutical company focused on treatments for central nervous…

Intra-Cellular Therapies: Parkinsons Disease Drug Expansion Could Be The Next Huge Move

…

Intra-Cellular Therapies to Host Third Quarter 2024 Financial Results Conference Call and Webcast

NEW YORK, Oct. 17, 2024 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the…

Intra-Cellular Therapies, Inc. (ITCI) Q2 2024 Earnings Call Transcript

…

Intra-Cellular Therapies: Downgrade

Zürich (www.aktiencheck.de) - Rating-Update: Die Analysten der UBS stufen die Aktie von Intra-Cellular Therapies Inc. (ISIN: US46116X1019, WKN: A1XDTL, Ticker-Symbol: 23I,…

Intra-Cellular Therapies: Kursziel gesteigert

New York (www.aktiencheck.de) - Rating-Update: Die Analysten von Mizuho Securities USA bewerten die Aktie von Intra-Cellular Therapies Inc. (ISIN: US46116X1019, WKN:…

Intra-Cellular Therapies: Klares Upside-Potenzial - Aktienanalyse

Kulmbach (www.aktiencheck.de) - Intra-Cellular Therapies-Aktienanalyse von "Der Aktionär": Michel Doepke vom Anlegermagazin "Der Aktionär" nimmt in einer aktuellen Aktienanalyse die Aktie…

Alzheimer’s Disease Treatment Stocks: 3 Biggest NASDAQ Companies in 2024

Alzheimer’s disease treatment stocks are focused on Alzheimer’s disease, a degenerative brain disorder that results in declining memory and thinking…

Intra-Cellular Therapies to Present at the 45th Annual Goldman Sachs Global Healthcare Conference

NEW YORK, June 10, 2024 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on…

Intra-Cellular Therapies: Positive MDD Data And Commercial Momentum Make It A Buy

…

Intra-Cellular Therapies to Present at the 44th Annual TD Cowen Health Care Conference

NEW YORK, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on…

dpa-AFX ProFeed